Toremifene Citrate 60mg

Toremifene Citrate (commonly known by its brand name Fareston) is an oral, second-generation Selective Estrogen Receptor Modulator (SERM). Derived as a chlorinated derivative of Tamoxifen, Toremifene was developed to retain potent tissue-selective anti-estrogenic benefits while significantly reducing the hepatic toxicity, ocular side effects, and DNA-adduct formation risks associated with older SERMs.

Clinically indicated for the treatment of estrogen receptor-positive ($ER+$) metastatic breast cancer in postmenopausal women, Toremifene acts as a competitive estrogen antagonist in target tissues like breast tissue, while functioning as an agonist in bone and lipid pathways. In endocrine and post-cycle recovery protocols, a 60mg formulation serves as a core standard daily dose to prevent estrogenic side effects (such as gynecomastia) and stimulate endogenous gonadotropin secretion to restore natural testosterone production.

Key Benefits & Applications

• Targeted Gynecomastia Prevention: Competitively binds to estrogen receptors in mammary gland tissue, blocking circulating estradiol ($E_2$) to prevent or reverse gynecomastia.

• HPTA Axis Restoration: Inhibits central estrogenic negative feedback at the hypothalamus and anterior pituitary gland, driving a significant surge in Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) to restart endogenous testosterone production.

• Favorable Safety Profile: Chlorine substitution reduces the risk of genotoxic DNA damage and ocular side effects compared to first-generation SERMs like Tamoxifen.

• Support for Blood Lipid Profiles: Acts as an estrogen agonist in hepatic tissues, helping reduce LDL cholesterol while preserving HDL cholesterol levels during hormone protocols.

• Preservation of Bone Mineral Density: Functions as an estrogen agonist in bone tissue, helping maintain bone density during phases of altered circulating sex hormones.